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Abstract
In addition to its eﬃcacy in the treatment of multiple myeloma, the proteasome inhibitor bortezomib appears to be active against
a variety of other haematological malignancies. In a phase II trial, bortezomib, given twice weekly for 2 weeks of a 3 week cycle to
patients with relapsed, refractory or untreated indolent non-Hodgkin’s lymphoma (NHL) or mantle cell lymphoma (MCL), pro-
duced durable responses in 2/7 MCL patients and stable disease in ﬁve. Six of eight patients with follicular NHL achieved a durable
response (1 CR, 5 PR). In another study, bortezomib was administered to patients with relapsed or refractory indolent or aggressive
B-cell lymphoma. Durable responses were seen in 7/12 MCL patients, including three CR. This apparent activity in MCL is par-
ticularly encouraging, given its poor prognosis. These early trial results demonstrate that further clinical testing of bortezomib and
additional exploration of the multiple biologic eﬀects of proteasome inhibition are warranted in lymphoproliferative malignancies.
 2004 Elsevier Ltd. All rights reserved.
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In addition to the positive results already obtained in
the treatment of multiple myeloma [1], preclinical and
early clinical data indicate that the proteasome inhibitor
bortezomib may be active against a variety of other
haematological malignancies. The proteasome regulates
the activity of many proteins involved in cell growth and
apoptosis, including nuclear factor-jB (NF-jB). The
survival of cell lines from patients with diﬀuse large B-
cell lymphomas has been shown to depend on consti-
tutive NF-jB expression [2,3]. Inhibition of constitutive
NF-jB activity by bortezomib in mantle cell lymphoma
leads to induction of cell cycle arrest and apoptosis [4].
Proteasome inhibition also induces rapid and extensive
apoptosis of leukaemic cells, but leaves normal hae-
matopoietic stem cells viable [5,6].
Preliminary evidence of the activity of bortezomib
against non-Hodgkin’s lymphoma (NHL) was demon-
strated in a phase I study in patients with haematological* Tel.: +1-212-639-8889; fax: +1-212-639-2767.
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doi:10.1016/j.ejcsup.2004.04.005malignancies. One patient with mantle cell lymphoma
and one with follicular lymphoma attained partial
remission [7].
In a phase II study in patients with relapsed or re-
fractory indolent lymphomas, 14 patients (accrual on
the trial is ongoing and will be updated accordingly)
were treated with bortezomib at a dose of 1.5 mg/m2
twice weekly for 2 weeks with a 1-week rest period [8].
Re-staging studies were performed after two complete
cycles of therapy. Of seven patients with follicular
lymphoma, one achieved a complete remission (CR) and
two achieved a partial remission (PR); two of two pa-
tients with small lymphocytic lymphoma achieved only
stable disease; and three of ﬁve patients with mantle cell
lymphoma achieved a PR after two cycles of treatment.
The results of this trial support the clinical activity of
bortezomib in patients with a variety of NHL subtypes.
Preliminary results from another phase II study of
bortezomib in patients with relapsed or refractory in-
dolent and aggressive B-cell lymphomas are also en-
couraging [9]. Investigators from the M.D. Anderson
Cancer Center in Houston, Texas, have reported on 11
patients treated with bortezomib at a dose of 1.5 mg/m2
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seven evaluable patients with mantle cell lymphoma, ﬁve
responses were observed, including one CR and two
PRs; these met the formal criteria for response. One
patient with follicular lymphoma had stable disease.
Principal toxicities included grade 3 and 4 gastrointes-
tinal toxicity (nausea, vomiting and/or diarrhoea),
thrombocytopaenia, and hypotension. Based on the
collective experience in NHL, further clinical evaluation
of bortezomib is ongoing.
A number of other clinical trials to assess the eﬃcacy
and safety of bortezomib in patients with other hae-
matological malignancies are currently underway.
Bortezomib is being evaluated for the treatment of
Waldenstr€om’s macroglobulinaemia, myelodysplastic
syndrome, acute myelogenous leukaemia, and chronic
myelogenous leukaemia. Given the potentially impor-
tant role of the proteasome pathway in the regulation of
haematological tumour cell growth and survival, the
results of these studies are awaited with interest.2. Indolent non-Hodgkin’s lymphoma and mantle cell
lymphoma: the need for new therapeutic strategies
The NHLs are at present the ﬁfth most common
cause of cancer-related death in the United States.
Collectively, they account for approximately 4–5% of all
cancer-related deaths in Caucasian and Hispanic popu-
lations and about 2% in African–American populations.
However, because some forms of NHL tend to aﬄict a
younger population, the years of life lost is greater than
in most other malignancies. This ranks NHL fourth
among all cancers with regard to their economic impact
in the United States. This year, it is estimated there will
be approximately 53,600 new cases of NHL, with over
23,800 deaths attributed to the disease. Thus, the case-
fatality rate for NHL (i.e. the number of deaths attrib-
uted to the disease/the incidence of the disease) is
approximately 44%. As with most haematological ma-
lignancies, there is a slight male predominance, with
about 57% of all cases developing in males.
The low-grade NHLs comprise approximately one-
third of all NHLs. Low-grade lymphoproliferative dis-
orders (including chronic lymphocytic leukaemia (CLL),
small lymphocytic lymphoma (SLL), the follicular
lymphomas, marginal zone lymphomas, and lympho-
plasmacytoid lymphoma (i.e. Waldenstr€om’s macro-
globulinaemia)) represent a class of diseases that are
characterized by slow progressive tumour growth that
responds to conventional cytotoxic therapies, in partic-
ular alkylating agents. While complete and partial re-
missions can be obtained in most patients, over time the
disease becomes increasingly more refractory to che-
motherapy. A variety of treatment modalities are used
to treat low-grade lymphomas. Patients with early-stagedisease may be treated initially with localized external
beam radiation, which may be curative in some small
fraction of patients. Unfortunately, more than 90% of
patients present with more disseminated disease and
cannot be cured by currently available treatment mo-
dalities. The response rates in newly diagnosed patients
treated with chemotherapy range from 60% to 80%,
while the median duration of response is approximately
2–3 years. Treatment of recurrent or unresponsive dis-
ease can vary considerably and can involve the admin-
istration of alkylator-based treatments like R-CVP/R-
CHOP and chlorambucil, purine-analogue-based ther-
apy with ﬂudarabine, or biologically based therapies
with rituximab, interferon, or radioimmunotherapy. In
patients with low-grade NHL, the response rate and the
duration of response substantially decrease with each
sequential course of chemotherapy. Hence, there is a
need to identify new agents that are either non-cross-
resistant with these prior conventional therapies or
that potentially synergize eﬀectively with the existing
treatments.
Mantle cell lymphoma is a considerably more diﬃcult
disease to treat. Overall, the median survival is in the
range of 3–4 years, with a median duration of response
of only about 18 months. Typically, the duration of
response to subsequent lines of therapy shorten by
about 50% with each new line of therapy. While there is
no standard of care for patients with this incurable
lymphoma, conventional chemotherapy programs like
R-CHOP typically produce response rates of about 40–
45%, with some more aggressive regimens like Hy-
perCVAD achieving higher complete response rates.
The addition of an anthracycline has been shown to
improve the number of CRs, and achieving a CR is
associated with a longer overall survival. While major
remissions can be seen with standard CHOP like che-
motherapy programs, the major clinical obstacle re-
mains the durability of response. Mantle cell lymphoma
is characterized by a gradually increasing pattern of
relapse with successive treatment programs, regardless
of the chemotherapy.
Biologically, the molecular changes described in CLL
and SLL are heterogeneous. Rearrangements involving
a number of diﬀerent chromosomal sites and oncogenes,
including bcl-1, bcl-2, and bcl-3, in addition to deletions,
additions, and translocations of chromosomes 11, 12,
13, 14 and 16 have been described in both CLL and
SLL. Although originally noted in B-cell CLL, bcl -1
rearrangements have been found in only a minority of
patients with CLL or SLL, but are commonly found in
mantle cell lymphomas (an aggressive chemoresistant
lymphoma). In contrast, rearrangements of the bcl-2
proto-oncogene are characteristic of follicular lympho-
mas and exist in about 20% of diﬀuse large cell lym-
phomas, while over-expression of bcl-2 is commonly
observed in CLL cells. Although proteasome inhibition
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CLL cells in vitro (which are 10–20 times more sensitive
than normal human lymphocytes), there is a strong
biological rationale to assess the clinical activity of
proteasome inhibition in other indolent lymphoprolif-
erative disorders where bcl-2 over-expression is well
characterized. Pharmacological manipulations that can
potentially override the cytoprotective eﬀects of bcl-2
over-expression may aﬀord new opportunities for
treating these otherwise incurable diseases.3. The ubiquitin–proteasome pathway: a novel anticancer
target
The major pathway for the degradation of intracel-
lular protein in eukaryotes is the ubiquitin–proteasome
pathway [10]. The workhorse of the pathway is the 26S
proteasome, an ATP-dependent, multi-catalytic prote-
ase. Fig. 1 depicts a schematic of this pathway. Target
cytosolic proteins are recognized by a ubiquitin-enzyme
complex, which binds to the N-terminus of the protein.
In an ATP-dependent reaction, the enzyme complex
catalyses the ubiquitination of the -amino moieties of
internal lysine residues. This ubiquitin molecule (a 76
amino acid protein) functions as a tag that is recognised
by the 19S regulatory subunit, which when complexed
with the 20S proteolytic core, forms the 26S proteasome.
Once the target protein is recognised by the regulatory
subunit, allosteric changes facilitate the internalisation
of the protein into the cylindrically shaped proteasome,
bringing it into close proximity with the internal prote-
ases. Once the protein is cleaved, it is discharged
through the opposite end. This pathway plays a vital
role in degrading regulatory proteins that govern cell
cycle control, transcription factor activation, apoptosis,
and cell traﬃcking, including p53, p21, p27, NF-jB, and
bcl-2 [10–13]. Preclinical observations have suggestedN-Pyrazinecarbonyl- L-phenylalanine- L-leucine boronic acid
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Fig. 1.that inhibitors of the ubiquitin–proteasome pathway,
agents like lactacystin and the calpain inhibitor ALLN
and ALLM, and bortezomib can act through multiple
mechanisms to arrest tumour growth, tumour spread,
and angiogenesis [5,6,14,15]. Phase I trials have con-
ﬁrmed tolerability of the drug and have suggested pos-
sible clinical activity [7,16].
The ubiquitin–proteasome pathway is essential for
transcriptional regulation. Nuclear factor-jB (NF-jB) is
a key transcription factor that is responsible for the
activation of genes that promote cell proliferation, cy-
tokine release, anti-apoptosis, and changes in cell sur-
face adhesion molecules. NF-jB is tightly regulated by
the ubiquitin–proteasome pathway through the accu-
mulation or degradation of IjB, which binds to and
inactivates NF-jB [13,17]. Cell adhesion molecules
(CAM) such as E-selectin, ICAM-1, and VCAM-1 are a
set of proteins regulated by NF-jB and are involved in
tumour metastasis and angiogenesis in vivo [18]. During
metastasis, these molecules direct the adhesion and ex-
travasation of tumour cells to and from the vasculature.
As such, tumour cell metastasis may well be contained
by the down-regulation of NF-jB-dependent cell adhe-
sion molecule expression. NF-jB is also required by
many cells to maintain cell viability as an anti-apoptotic
controlling factor [19]. Numerous lines of data now
suggest that inhibiting NF-jB activation by stabilising
the IjB protein makes cells more sensitive to environ-
mental stress, including chemotherapeutic drugs, ulti-
mately leading to programmed cell death.
Pre-clinical and clinical studies suggest that inhibitors
of the ubiquitin–proteasome pathway are a novel and
eﬀective means of inducing apoptosis and arresting tu-
mour growth, tumour spread, and angiogenesis. Drugs
that can pre-empt the activation of genes capable of
inducing various survival signals oﬀer a novel way to
intervene in tumour progression.4. What is bortezomib?
Bortezomib (N-pyrazinecarbonyl-L-phenylalanine-L-
leucine boronic acid, trade name VELCADE, formerly
known as PS-341 [CAS # 179324-69-7]) was supplied by
the Division of Cancer Treatment and Diagnosis,
National Cancer Institute. The chemical structure is
presented in Fig. 2. Bortezomib is a dipeptidyl boronic
acid inhibitor with high speciﬁcity for the 26S protea-
some [20]. It is the ﬁrst member of a new class of anti-
tumour agents to come to human trials. Several phase
I/II clinical studies have demonstrated that bortezomib
is a well-tolerated agent with a short-lived thrombocy-
topaenia as the major dose-limiting toxicity. In addition,
it has been shown that bortezomib is capable of pro-
ducing a dose-related eﬀect on proteasome inhibition
when analysed 1-h post infusion with little inter-patient
Table 2
Major toxicities
Total number of patients
Thrombocytopaenia Grade 1¼ 6 (30%)
Grade 2¼ 6 (30%)
Grade 3¼ 2 (10%)
Grade 2¼ 1 (5%)
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O.A. O’Connor / EJC Supplements Vol 2 No. 6 (2004) 18–24 21variability, with responses at the lowest doses studied to
date [7]. Recently, bortezomib was approved by the US
Food and Drug Administration for the treatment of
relapsed or refractory multiple myeloma, and was also
recently recommended for approval in Europe for pa-
tients with multiple myeloma who have received at least
two prior therapies.
Sensory neuropathy Grade 3¼ 1 (5%)
Motor neuropathy Grade 2¼ 1 (5%)
Grade 3¼ 1 (5%)
Small vessel necrotizing vasculitis (new) Grade 2¼ 2 (10%)
Lymphopaenia Grade 3¼ 5 (25%)
Table 3
Patient Response Data
Diseasea Response % Reduction in
Tumour Volume
Duration
(months)
Follicular NHL CR¼ 1 100 6 +
PR¼ 5 50–60 3–12 +
(8/9 evaluable) SD¼ 1 – 2–6
POD¼ 1 – –
Mantle cell NHL PR¼ 2 54–80 6–17
SD¼ 5 0–35 3–6 +
(7/8 evaluable)
SLL/CLL SD¼ 2 – 3–6 +5. The MSKCC phase II experience
This study is a single-center, single-agent phase II
study of bortezomib in patients with relapsed, refractory
or untreated indolent NHL and mantle cell lymphoma.
The major objectives of the study were to determine the
frequency and duration of complete and partial response
rates for patients with indolent lymphoproliferative
disorders treated with bortezomib.
Table 1 presents some of the characteristics of these
patients; Table 2 presents toxicity data; and Table 3
shows the early response data. Patients were required to
have histologically conﬁrmed lymphoma using the
REAL classiﬁcation, including: chronic lymphocytic
leukaemia; B-cell small lymphocytic lymphoma; anyTable 1
Patient demographics
Total number of patients 21
Disease
Follicular 9 (43%)
Mantle cell lymphoma 8 (38%)
Marginal zone lymphoma 1 (5%)
Small/Chronic lymphocytic lymphoma 3 (14%)
Median baseline Karnofsky status (range) 90% (80–90%)
Median age (range) 63 (44–78)
Gender 50% M / 50% F
Average number of prior therapies 2
(2/3 evaluable)
aOne patient with marginal zone lymphoma.marginal zone lymphoma; follicle center cell lymphoma,
grades 1, 2, or 3; mantle cell lymphoma and Wald-
enstr€om’s macroglobulinaemia. Patients with trans-
formed lymphoma were allowed as long as they received
appropriate chemotherapy for their aggressive disease in
the past and on subsequent biopsies had no evidence of
aggressive lymphoma. To be eligible for enrollment,
patients had to meet the usual criteria, including the
following: (1) have measurable disease deﬁned by NCI
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received no more than three prior regimens of conven-
tional cytotoxic therapy and be oﬀ all cytotoxic chemo-
therapy for at least 4 weeks prior to study enrollment; (3)
have a period of at least 3 months since the last admin-
istration of any monoclonal antibody; (4) be 18 years of
age or older and sign informed consent; (5) have a life
expectancy of 3 months or greater; (6) have a Karnofsky
performance status >60%; (7) have no sign of congestive
heart failure according the New York Heart Failure
Guidelines Class III/IV.
In addition, patients were required to meet the fol-
lowing criteria within 2 days of study drug administra-
tion: an absolute neutrophil count >1500/lL (if known
lymphomatous involvement of the bone marrow, then
>500/mL); a platelet count of P 50,000/lL for the ﬁrst
dose of every cycle and >30,000 for doses delivered on
days 4, 8 and 11; a total bilirubin <1.5 times upper
institutional limit; an AST(SGOT)/ALT(SGPT) 6 2.5
times institutional upper limit of normal (4 if liver
involvement); and a creatinine <1.5 upper institu-
tional limits. Patients were excluded if they were preg-
nant; had evidence of intracranial disease; had major
surgery within 4 weeks of study drug administration; or
had uncontrolled illness including active infection,
symptomatic congestive heart failure, uncontrolled hy-
pertension, unstable angina pectoris, cardiac arrhyth-
mia, a myocardial infarction or cerebrovascular accident
within 6 months of study enrollment, known HIV dis-
ease or psychiatric illness/social situations that would
limit compliance with study requirements.
Patients were treated twice weekly for 2 weeks (days
1, 4, 8 and 11) followed by a 1-week rest period (one
cycle). Patients who failed to meet the eligibility criteria
for re-treatment simply missed that dose and resumed
treatment once their haematological counts met the
stated criteria. Management of the patients’ anti-emetic
regimen, secondary anemia and neutropaenia were
based on standard institutional guidelines.
Response criteria for patients enrolled on study fol-
lowed the guidelines previously reported by Cheson et al.
[21]. To date, 21 patients have been registered for the
study. Of the 21 patients, a broad panoply of diﬀerent
indolent lymphomas, including 9 patients (43%) who had
follicular lymphoma, representing all possible grades, 8
patients (38%) with mantle cell lymphoma, 3 patients
with SLL and 1 patient with marginal zone lymphoma.
Themedian number of prior therapies for all patients was
two, with nearly 63% of all patients having received at
least one course of rituximab and most receiving multiple
courses of the antibody. The overwhelming majority of
patients had received prior alkylator-based treatment,
primarily CHOP or CVP-based chemotherapy with or
without rituximab. Only about 10% of patients received
prior purine analogue-based therapy, while two had re-
ceived prior radioimmunotherapy or peripheral bloodstem cell transplant. Overall, the drug was very well tol-
erated. The major toxicity that we already know to be the
practical dose-limiting toxicity was thrombocytopaenia,
though only two of the 21 patients experienced a grade 3
thrombocytopaenia. Typically, the platelet nadir seen in
patients receiving bortezomib is not very deep and is
usually very short-lived. Based upon this, the protocol
was recently amended to reduce the platelet count from
100,000 to 50,000 for the ﬁrst dose of any given cycle, and
30,000 for doses 2–4. Neuropathy was mostly grade 1,
and in all cases it resolved to baseline grade during the
rest week. One patient did develop a grade 2 sensory
neuropathy, and one patient developed a grade 3 sensory
neuropathy. This latter patient, however, went on to
develop a grade 3 sensorimotor neuropathy. Clinically,
this patient was strongly suspected of having leptome-
ningeal disease, but following an aggressive work-up in-
cluding MRI, lumbar punctures, and EMGs, no organic
basis for her neuropathy could be identiﬁed.
In addition to these toxicities, we also discovered
several patients who developed a vasculitic, like rash,
typically during the second cycle after the third or fourth
doses. Punch biopsy of some of these patients has con-
ﬁrmed a small vessel necrotising vasculitis. This rash is
inconsequential, has never required steroids, an is self-
limiting. The most common grade 3 toxicity was in fact
lymphopaenia, which is in and of itself and interesting
toxicity, given some of the response data in lymphoma
we will be discussing below.
To date, we have delivered 62.5 cycles of therapy, of
which there were a planned 278 doses, of which 254 were
actually delivered. The number of patients who missed at
least one dose was about one-third. This was primarily
attributed to low platelet counts (i.e. less than 100,000/
mL). Since we adjusted the platelet count criteria, the
number of reduced doses has fallen dramatically. Other
reasons for patients missing doses, though to a much
lesser extent, include fatigue and asthaenia. Nine of 21
patients required dose reductions to 1.3 mg/m2, of which
about 4 of these patients required dose reductions to
1.1 mg/m2, again mostly due to thrombocytopaenia.
The preliminary response data are based on 19
evaluable patients (Table 3). One of the more interesting
features of the response data is the dramatic diﬀerence
seen among the diﬀerent subtypes of lymphoma. While
these are admittedly very small numbers, of 8 evaluable
patients with follicular lymphoma, six achieved a major
response, including one complete remission and ﬁve
partial remissions. In all patients achieving a response,
the response was conﬁrmed. The patient who achieved
the complete remission actually had a duration of re-
sponse of approximately 9 months, which was longer
than that which she had achieved with her prior line of
chemotherapy. In the patients with mantle cell lym-
phoma, seven of the eight patients were evaluable for
response. Two have had partial remissions, while the
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these patients, they remain on active treatment, and it
may be too early to determine their overall response as
of yet. One of the patients who achieved a partial re-
mission had attained a 6-month duration of remission
from CHOP followed by rituximab. After four cycles of
therapy, he achieved over an 80% shrinkage of his dis-
ease, which has lasted over 19 months. Once his re-
sponse had exceeded 6 months, we again amended the
protocol to allow patients maintaining a durable re-
sponse to be re-treated. The patient went on to receive a
second course of bortezomib, again attaining a second
major partial remission that is durable and still in active
follow-up 2 months post bortezomib.
Interestingly, no patient with small lymphocytic
lymphoma to date has responded, though all have had
only stable disease at best. One patient with marginal
zone lymphoma just enrolled in the study has demon-
strated a PR after only two cycles of bortezomib, though
he is still on active treatment.6. Other experiences with bortezomib in lymphoma
In addition to our study, Dr. Andre Goy at M.D.
Anderson Cancer Center in Texas has also been con-
ducting a single-agent, single-institution study of bort-
ezomib in patients with any B-cell neoplasm, regardless
of their prior number of treatments. In his presentation
at the American Society of Clinical Oncology earlier this
year, Dr. Goy reported on 24 patients with a median age
of 60 years. Nearly half of the patients he has enrolled to
date had mantle cell lymphoma, while the remainder
primarily had diﬀuse large B-cell lymphoma. Overall, his
population of patients was more heavily pre-treated,
with a median number of prior therapies of 3.2. The
overwhelming majority of patients had markedly ele-
vated LDH and b2-microglobulin prior to study en-
rollment. Thus far, he has delivered about 52 cycles of
therapy, with a mean of 2.1 cycles per patient. Overall,
these patients appear to be receiving somewhat less total
therapy, which is most likely due to their extensive prior
treatment histories. Thus far, four patients have had to
discontinue treatment: two secondary to diarrhoea and
subsequent hypotension, one due to neuropathy, and
one due to thrombocytopaenia. Of note, and though not
yet studied in a prospective fashion, Dr. Goy has found
that administering 500 to 1000 mL of intravenous nor-
mal saline weekly seems to help reduce the asthaenia and
fatigue associated with the drug administration.
Of 12 patients with mantle cell lymphoma, seven
patients have achieved a major response, three of whom
achieved complete remission. In all cases, these re-
sponses have been conﬁrmed. Of those patients with
diﬀuse large B-cell lymphoma, only one patient experi-
enced a partial remission, the others all developedprogression of disease on study. One patient with SLL
had only stable disease on study.7. Summary
Collectively, the data to date suggest that bortezomib
has signiﬁcant activity in a number of lymphoprolifera-
tive malignancies. To date, follicular lymphoma and
mantle cell lymphoma appear to be amongst the most
responsive diseases to bortezomib. The conﬁrmed ac-
tivity in mantle cell lymphoma may raise a number of
important research opportunities for this disease, espe-
cially given its poor prognosis. The ability to achieve
durable complete or partial remissions, coupled with the
prospect of administering additional cycles of the drug
upon relapse, may oﬀer a unique therapeutic strategy
that may improve the durability of response to a single
agent. It also raises the interesting idea that in this known
poor-risk population of patients, a maintenance-like
schedule of bortezomib could aﬀord some additional
beneﬁt with regard to the durability of the response.
Another intriguing observation to emerge from both
studies pertains to the diﬀerent response rates among the
diﬀerent sub-types of lymphoma. Why did patients in
Dr. Goy’s study with refractory diﬀuse large B-cell
lymphoma fail to achieve any response? It has been
shown that NF-jB over-expression is a molecular fea-
ture that appears to characterize these refractory ag-
gressive lymphomas, and given the ability of bortezomib
to interfere with this pathway speciﬁcally, it is unclear
why these types of lymphomas fail to respond.
What is clear is that there is also a wealth of
pre-clinical data that suggest that inhibition of the
proteasome potently synergises with numerous other
conventional cytotoxic therapies, including cyclophos-
phamide, vincristine, gemcitabine, and even prednisone.
One of the theories belying this interaction revolves
around the stress response mediated by NF-jB. For
those cells not killed outright by exposure to some con-
ventional cytotoxic agent, say irinotecan for example,
those cells that survival tend to be characterized by very
high levels of NF-jB, which facilitate cell proliferation
and anti-apoptosis, providing a survival advantage for
those cells. Co-administration of an agent like bortezo-
mib, which could blunt that NF-jB response, could well
compromise the survival response, leading to augmented
activity. In fact, many pre-clinical studies have demon-
strated this mechanism to be important in drug combi-
nation studies of bortezomib. It is clear, however, that
much future eﬀort will need to be devoted to under-
standing the panoply of eﬀects mediated by proteasome
inhibition and how these eﬀects are likely to change from
tissue to tissue, and cancer to cancer. Bortezomib re-
mains a drug with a single target, but capable of pro-
ducing a multiplicity of biological eﬀects.
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